Bayer company profile
Company profile
Bayer has 87,775 employees and is headquartered in Leverkusen, Germany.
Known for prescription medicines in cardiology and women's health, contrast agents for diagnostic imaging, and over-the-counter products for self-medication, Bayer also sells crop protection products, seeds and digital farming solutions. Its Pharmaceuticals, Consumer Health and Crop Science segments reach customers through wholesalers, pharmacies, supermarkets, online and other retailers, and hospitals, while farmers are supplied directly. The company operates in Europe, Germany, Switzerland, North America, the United States, Asia Pacific, China, Latin America, Brazil, Africa and the Middle East.
Bayer was founded in 1863 and is headquartered in Leverkusen, Germany. In the fiscal year ended 31 December 2025, revenue fell 2.2% to 45.6 billion euros and the group reported a net loss of 3.6 billion euros. The company employed 87,775 people. Its strategic alliances include work with The University of Colorado Anschutz, UCHealth and Children's Hospital Colorado on drug development and clinical trials, as well as a strategic alliance with Henry Ford Health.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Germany
- Headquarters
- Kaiser-Wilhelm-Allee 1, 51368, Leverkusen
- Employees
- 87,775
- Chief executive
- William Anderson
- Founded
- 1863
- Fiscal year
- January - December
- Listing
- BAYN · Xetra
- Indices
- DAXEURO STOXX 50
- Currency
- EUR
- ISIN
- DE000BAY0017
- Website
- bayer.com
Bayer and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| BayerBAYN | Germany | $61.37B | 87,775 | 16.5% | — |
| GSKGSK | United Kingdom | $101.36B | 66,841 | 30.5% | 17.9 |
| SanofiSAN | France | $116.24B | 74,846 | 22.3% | 25.3 |
| Novo NordiskNOVO.B | Denmark | $181.48B | 68,794 | 50.8% | 10.9 |
| OrionORNAV | Finland | $15.93B | 4,215 | 38.1% | 22.0 |
| AstraZenecaAZN | United Kingdom | $286.82B | 96,100 | 25.8% | 26.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
